Objective To discuss the influence of Saccharomyces boulardii on serum apolipoprotein levels in liver cirrhosis patients with spontaneous bacterial peritonitis (SBP).Methods 74 liver cirrhosis patients with SBP were selected and randomly divided into the observation group and control group.Patients in the two groups were given routine medical treatment such as liver protection and diuretic effect,correction of hypoproteinemia,anti-infection etc.Patients in the observation group were orally given Saccharomyces boulardii 0.5g for one time,two times daily for 4 weeks.The changes of serum apolipoprotein A1 and B levels in two groups were observed and compared,and the curative effect and safety were also observed.Results After treatment for 4 weeks,the serum apolipoprotein A1 and B levelsintwogroupswereobviouslyincreasedcomparedwithbeforetreatment (t =2.46,2.3 7,3.04,2.87,P ＜ 0.05or P ＜0.01),and the increase of observation group was much higher than that of control group(t =2.29,2.23,all P ＜ 0.05).Meanwhile,the total effective rate of the observation group (91.89％) was significantly higher than that of control group (72.97 ％) (x2 =4.57,P ＜ 0.05).3 cases and 5 cases of adverse reactions appeared in control group and observation group,the symptom was light and no serious drug adverse reaction(DAR) observed.The incidence rate of DAR between the two groups had no obviously statistical difference (x2 =0.14,P ＞ 0.05).Conclusion Saccharomyces boulardii has reliable curative effect and high security in the treatment of liver cirrhosis patients with SBP,the mechanism may be related with increasing the synthesis of apolipoprotein A1 and B in the liver and intestine,and increasing serum levels of apolipoprotein A1 and B.

Objective To explore the ursodeoxycholic acid efficacy and safety analysis of nucleoside drugs for HBeAg-positive with high viral load in patients with liver cirrhosis, and its effect on peripheral blood Th17, Treg levels.Methods 80 patients with high viral load B HBeAg-positive from November 2012 to February 2014 were selected and randomly divided into control group and observation group, 40 cases in each group.Patients in control group received conventional treatment, observation group was treated with ursodeoxycholic acid based on the control group, antiviral efficacy and adverse reactions, peripheral blood Th17, Treg levels were compared between two groups.Results After treatment, the ALT, AST, ALB, TBil levels between two groups were significantly lower compared with before treatment(P<0.01), the ALT, AST, ALB, TBil levels in observation group were significantly lower than the control group ( P<0.01 ); HBV-DNA negative rate ( 85.0%) and decrease of HBV-DNA in observation group were significantly higher (7.5%) than those in control group, the difference was statistically significant (χ2 =48.322, t =11.490, P<0.01); ALT normalization rate (52.5%), HBeAg seroconversion rate (57.5%) in observation group was significantly higher than those in control group(15.0%, 17.5%), the difference was statistically significant (χ2 =12.579,χ2 =13.653, P<0.01);complications compared with the situation observed group of death, hepatocellular carcinoma, spontaneous bacterial peritonitis, gastrointestinal bleeding compared with control group, the difference was not statistically significant (χ2 =1.01, χ2 =2.05, χ2 =3.12, χ2 =0.21, P>0.05).After treatment, the Th17 levels elevated, Treg level decreased in two groups, Th17 level in observation group was significantly higher than control group, Treg levels were significantly lower than the control group, Th17/Treg ratio was higher than the control group (P<0.05).Conclusion Ursodeoxycholic acid can significantly improve liver function of patients with HBeAg positive with high viral load, increase the rate of HBeAg seroconversion, inhibit HBV viral replication and delay progression of the disease, and less adverse reactions.It can increase the number of Th17 cells, reduce the number of Treg cells in patients, which may be one of its antiviral mechanism.